Loading...
01/10 20:13
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial metrics, optimistic guidance, and strategic growth initiatives. The company expects significant growth in Afrezza sales and FUROSCIX, supported by investments in sales force expansion and new product developments. The strategic financing with Blackstone provides a substantial non-dilutive funding boost. Market opportunities, especially in the NTM market, are promising, and the company is confident in its pricing model. Despite some unclear management responses, the overall sentiment is positive, with potential catalysts like the Afrezza label update and ReadyFlow injector expansion.
Total Revenue $82 million in Q3 2025, a 17% increase year-over-year, driven primarily by royalties earned on Tyvaso DPI.
Tyvaso DPI Royalties $33 million in Q3 2025, a 23% increase year-over-year, reflecting strong performance under collaboration with United Therapeutics.
Collaboration and Services Revenue $27 million in Q3 2025, up 14% year-over-year, primarily from manufacturing revenue and deferred revenue recognition.
Afrezza Net Revenue $18.5 million in Q3 2025, a 23% increase year-over-year, driven by a 31% growth in new prescriptions and 27% growth in total prescriptions, despite a 15% decline in units per script due to a focus on type 1 diabetes.
VGo Revenue $3.8 million in Q3 2025, a 19% decrease year-over-year, consistent with the company's decision to no longer actively promote the product.
FUROSCIX Revenue $19.3 million in Q3 2025, with year-to-date revenue reaching $47.1 million, a 95% increase year-over-year, driven by expanded sales force and increased prescribing adoption.
GAAP Net Income $8 million in Q3 2025, compared to $11.6 million in Q3 2024, reflecting acquisition-related expenses and investments in growth.
Non-GAAP Net Income $22.4 million in Q3 2025, up from $15.4 million in Q3 2024, reflecting strong operational performance despite significant investments in future growth.
Afrezza supplemental BLA: Accepted for review with a PDUFA date of Q2 2026. If approved, it will be the first new insulin for pediatric patients in over 100 years.
FUROSCIX auto-injector: sNDA submitted to the FDA in Q3 with an expected PDUFA date of Q3 2026. This device aims to simplify admissions, expand treatment options, and reduce costs.
Tyvaso DPI: Generated $59 million in royalty and manufacturing-led revenue in Q3. Developed an 80-microgram cartridge to improve patient convenience.
Bumetanid DPI (MNKD-701): Advanced into preclinical development for fluid overload in CKD and heart failure.
scPharmaceuticals acquisition: Acquisition completed, adding FUROSCIX to MannKind's portfolio and expanding into cardiorenal medicine.
Heart failure and CKD market: Large unmet need with 2.1 million addressable heart failure episodes in the U.S. FUROSCIX targets this market by reducing hospital admissions and readmissions.
Tyvaso DPI label expansion: Potential to expand label to include IPF and/or PPF contingent upon FDA approval.
Revenue growth: Achieved record revenue of $82 million in Q3 2025, a 17% increase year-over-year.
FUROSCIX sales: 27,000 doses dispensed in Q3, up 153% year-over-year. Revenue reached $19.3 million in Q3.
Afrezza sales: Net revenue grew 23% in Q3 2025 compared to Q3 2024. New prescriptions grew 31% year-over-year.
Expansion into pediatrics: Enhanced messaging and expanded field force to target top 50 pediatric centers for Afrezza.
CMS ambulatory specialty model: Aligning FUROSCIX strategy with CMS's new risk-based payment model for heart failure care starting in January 2027.
Collaboration with United Therapeutics: Expanded collaboration to include a second investigational molecule using MannKind's Technosphere technology.
Regulatory hurdles: The company faces regulatory risks with multiple submissions to the FDA, including the sNDA for FUROSCIX auto-injector and Afrezza sBLA for pediatric use. Delays or rejections could impact product launches and revenue growth.
Supply chain and manufacturing challenges: The company relies heavily on manufacturing partnerships, such as with United Therapeutics for Tyvaso DPI. Any disruptions in manufacturing or supply chain could adversely affect revenue and product availability.
Financial risks: The company has taken on significant financial commitments, including a $325 million term loan facility with Blackstone and the $133 million acquisition of scPharmaceuticals. These financial obligations could strain cash flow and limit flexibility.
Market competition: The company operates in highly competitive markets, including diabetes care and cardiometabolic medicine. Competitors with more resources or established products could limit market share growth.
Strategic execution risks: The integration of scPharmaceuticals and the expansion of the sales force for FUROSCIX require significant operational focus. Any missteps could delay growth and impact financial performance.
Economic uncertainties: Broader economic conditions, including Medicare spending changes and CMS's new risk-based payment model, could impact the adoption of FUROSCIX and other products.
Clinical trial risks: The company is heavily reliant on the success of its clinical trials, such as the ICoN-1 Phase III study and INFLO Phase II study. Delays or failures in these trials could hinder pipeline progress and future revenue.
Afrezza Pediatric Indication: Afrezza's supplemental BLA was accepted for review with a PDUFA date of Q2 2026. If approved, it will be the first new insulin for pediatric patients in over 100 years. The company is initiating the 'Inhaled First' study to position Afrezza as the first-choice bolus insulin for youth aged 10 to 18 newly diagnosed with type 1 diabetes. This study will evaluate safety and efficacy across 10 leading sites.
FUROSCIX Auto-Injector: The sNDA for FUROSCIX auto-injector was submitted to the FDA in Q3 2025, with an expected PDUFA date of Q3 2026. If approved, this device will simplify admissions, expand treatment options, and reduce costs, enabling reinvestment in growth and margin improvement.
Tyvaso DPI Expansion: Following positive TETON-2 data, United Therapeutics plans to pursue a DPI bridging study in IPF, potentially expanding the Tyvaso DPI label to include IPF and/or PPF, contingent upon FDA approval.
ICoN-1 NTM Phase III Trial: Enrollment for the ICoN-1 NTM Phase III trial was completed ahead of schedule, with trial sizing confirmation expected mid-2026. The market for this indication is expected to exceed $1 billion by the end of the decade.
INFLO Phase II Study (MNKD-201): The INFLO Phase II study for Nintedanib DPI is set to begin enrolling patients in Q1 2026. This trial will evaluate safety, tolerability, and efficacy in 210 patients with IPF over 12 weeks, followed by a 6-month open-label extension.
Bumetanid DPI (MNKD-701): Advancing bumetanid DPI into preclinical development as a non-invasive solution for fluid overload in CKD and heart failure. This formulation aims to provide rapid, portable treatment options.
FUROSCIX Commercial Strategy: Post-acquisition, the focus is on expanding FUROSCIX's role in reducing hospital readmissions for heart failure and CKD patients. The strategy includes targeting post-discharge periods and aligning with CMS's new risk-based payment model starting January 2027.
Revenue Growth Projections: With the addition of FUROSCIX and continued growth in Tyvaso DPI royalties, the company anticipates significant revenue growth. Pro forma commercial product sales would represent 39% of total revenues year-to-date if FUROSCIX were included.
The selected topic was not discussed during the call.
The earnings call highlights strong financial metrics, optimistic guidance, and strategic growth initiatives. The company expects significant growth in Afrezza sales and FUROSCIX, supported by investments in sales force expansion and new product developments. The strategic financing with Blackstone provides a substantial non-dilutive funding boost. Market opportunities, especially in the NTM market, are promising, and the company is confident in its pricing model. Despite some unclear management responses, the overall sentiment is positive, with potential catalysts like the Afrezza label update and ReadyFlow injector expansion.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
